Make us your home page

Today’s top headlines delivered to you daily.

(View our Privacy Policy)

Biotech company Genzyme to pay $22.3 million in Tampa whistle-blower case

TAMPA — A Massachusetts-based biotechnology company has agreed to pay $22.28 million to resolve allegations brought by whistle-blowers in Tampa and Miami that it marketed an inappropriate use for a surgery medication, U.S. government attorneys said.

Genzyme, a corporation known for its research into drugs for rare genetic diseases, is paying the settlement in a lawsuit over Seprafilm, a material it manufactures for use in the operating room.

According to court documents, Genzyme sales representatives encouraged doctors to use the product in a manner not approved by the U.S. Food and Drug Administration, leading to improper claims for reimbursement from hospitals.

"I think these cases are among the most important that our office handles. Health care fraud is a major problem in our country," said A. Lee Bentley III, acting U.S. Attorney for the Middle District of Florida. "These do serve a very important deterrent effect."

The settlement is the result of a civil suit brought under the federal False Claims Act, a 19th-century law that encourages private citizens to expose fraud by government contractors. Whistle-blowers can file suit on behalf of the government and then share in any financial settlement that results.

The Genzyme action was brought by two company sales representatives in 2009.

The amount of the settlement that will be diverted to the whistle-blowers has not yet been determined. One of the private plaintiffs' attorneys, Barry Cohen of Tampa, said they hope to receive between 23 and 24 percent of the settlement, or about $5.2 million.

"They were pharmaceutical salesmen, and they recognized that this was a potential danger," Cohen said. "They saw other people doing it, and they knew it wasn't right."

Sarah Connors, a spokeswoman for Sanofi, Genzyme's parent company, said that Genzyme cooperated with the government investigation and that the company's sales force no longer markets Seprafilm for the unorthodox procedure that spawned the lawsuit.

"Genzyme did take proactive action to address and prohibit this conduct," she said.

According to court documents, Seprafilm is intended to be applied during open surgery to prevent organs and muscle tissue from sticking together. However, the whistle-blowers and lawyers for the federal government alleged that Genzyme sales representatives taught doctors to use it in less invasive procedures — such as laparoscopic or "keyhole" surgeries — by mixing it into a liquidlike "slurry" that could be injected into the body.

Cohen and Bentley said they were not required to prove in the lawsuit that patients had been harmed, only that this use of the drug was not approved by federal regulators and hence not subject to reimbursement by Medicare and Medicaid.

The hefty Genzyme settlement follows two other large payouts secured in recent years by the U.S. Attorney's Office and the Cohen Law Group, including a $217.5 million settlement from WellCare Health Plans and a $10.17 million settlement from Morton Plant Mease Health Care.

Peter Jamison can be reached at [email protected] or (813) 226-3337. Follow him on Twitter @petejamison.

Biotech company Genzyme to pay $22.3 million in Tampa whistle-blower case 12/23/13 [Last modified: Monday, December 23, 2013 11:27pm]
Photo reprints | Article reprints

© 2017 Tampa Bay Times


Join the discussion: Click to view comments, add yours

  1. Rick Baker debuts new campaign ad to woo younger voters


    Former mayor Rick Baker's campaign unveiled a reboot of sorts Tuesday with the debut of a new TV ad.

    Delores Green and mayoral candidate Rick Baker smile as they look at a selfie that Green took at a food truck food giveaway at Rick Baker's disaster assistance registration center on Central Ave. in St. Petersburg on Sept. 15.
  2. Editorial: DOT listens, adjusts on I-275 plans in Tampa


    Florida continues to improve its plan for modernizing the interstate system in Tampa Bay. The Florida Department of Transportation has unveiled four new options for rebuilding I-275 near downtown Tampa, and some of them would ditch previous plans for toll lanes downtown while keeping express lanes for faster, …

    State officials are re-evaluating parts of I-4 and I-275 in Tampa as part of a supplemental environmental impact study, or SEIS. 
  3. College basketball scandal dips into Tampa Bay


    Tuesday's national college basketball scandal has recruiting ties to Tampa Bay.

    In this March 15, 2012, file photo, San Diego State assistant coach Tony Bland, left, talks during NCAA college basketball practice in Columbus, Ohio. Bland was identified in court papers, and is among 10 people facing federal charges in Manhattan federal court, Tuesday in a wide probe of fraud and corruption in the NCAA, authorities said. [AP Photo/Tony Dejak, File]
  4. Datz to open in St. Petersburg, join the James Museum of Western and Wildlife Art

    Food & Dining

    Now Datz news.

    Get it? Tuesday, Datz, the longtime line-out-the-door, oft-Instagrammed and -Yelped Tampa stalwart known for shock-and-awe sandwiches and oh-so-much bacon, announced it is coming to St. Petersburg.

    Lunch guest eat at Datz Deli at 2616 South MacDill Ave. in Tampa. Times files.
  5. Republican leader McConnell pulls the plug on latest Obamacare repeal effort

    WASHINGTON --- Sen. Mitch McConnell on Tuesday officially pulled the plug on the latest plan to repeal the health care law, telling senators they will not vote on the measure and effectively admitting defeat in the last-gasp drive to fulfill a core promise of President Donald Trump and Republican lawmakers.

    Senate Majority Leader Mitch McConnell of Ky. listens during a news conference on Capitol Hill in Washington, Tuesday, Feb. 7, 2017, after the Senate confirmed Betsy DeVos as education secretary. DeVos was approved by the narrowest of margins, with Vice President Mike Pence breaking a 50-50 tie in a historic vote. (AP Photo/J. Scott Applewhite) DCSA119